Cochrane Hypertension

🆕Review update🆕 Pharmacotherapy for mild #hypertension cochranelibrary.com/cdsr/doi/10.10… In people with mildly elevated #BloodPressure (BP) without cardiovascular disease (CVD) or related health risks, BP meds may not reduce risk of death or of developing major CVD #SystematicReview

🚨ICYMI - Updated Cochrane #SystematicReview: Withdrawal of antihypertensive drugs in older people 💊 doi.org/10.1002/146518… "Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio" #CochraneEvidence #bloodpressure #deprescribing

ICYMI: Cochrane #hypertension review: #Riboflavin supplements for blood pressure lowering in adults cochranelibrary.com/cdsr/doi/10.10… 🤔 Very uncertain evidence for effect of riboflavin on #bloodpressure 🎯 Large, well‐conducted trials needed #SystematicReviews #CochraneEvidence

🆕#Deprescribing review! Deprescribing antihypertensive medications in older people: a systematic review and a meta-analysis pubmed.ncbi.nlm.nih.gov/41491674 Congratulations to Cochrane Hypertension's Dr. Wade Thompson, Dr. Carole Lunny and co-authors #hypertension #bloodpressure

ICYMI: Cochrane #hypertension review: #Riboflavin supplements for blood pressure lowering in adults cochranelibrary.com/cdsr/doi/10.10… 🤔 Very uncertain evidence for effect of riboflavin on #bloodpressure 🎯 Large, well‐conducted trials needed #SystematicReviews #CochraneEvidence

🆕 Cochrane #hypertension review: #Riboflavin supplements for blood pressure lowering in adults cochranelibrary.com/cdsr/doi/10.10… 🤔 Very uncertain evidence for effect of riboflavin on #bloodpressure 🎯 Large, well‐conducted trials needed #SystematicReviews #CochraneEvidence

🆕Review update🆕 Pharmacotherapy for mild #hypertension cochranelibrary.com/cdsr/doi/10.10… In people with mildly elevated #BloodPressure (BP) without cardiovascular disease (CVD) or related health risks, BP meds may not reduce risk of death or of developing major CVD #SystematicReview

ICYMI - Review update: Pharmacotherapy for mild #hypertension cochranelibrary.com/cdsr/doi/10.10… In people w/ mildly elevated #BloodPressure (BP) without cardiovascular disease (CVD) or related health risks, BP meds may not reduce risk of death or of developing major CVD #SystematicReview

🆕Review update: Pharmacotherapy for #hypertension in adults 60 years or older cochranelibrary.com/cdsr/doi/10.10… Tx healthy adults 60 yrs+ with moderate-severe HTN with antihypertensives reduced all‐cause mortality & probably reduced cardiovascular mortality/morbidity #SystematicReview

🚨ICYMI - Cochrane #SystematicReview Renin inhibitors versus angiotensin receptor blockers for primary #hypertension doi.org/10.1002/146518… #CochraneEvidence #Blogshot

🚨ICYMI - Updated Cochrane #SystematicReview: Withdrawal of antihypertensive drugs in older people 💊 doi.org/10.1002/146518… "Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio" #CochraneEvidence #bloodpressure #deprescribing

🚨Cochrane #SystematicReview 🎺 Renin inhibitors versus angiotensin receptor blockers for primary #hypertension doi.org/10.1002/146518… #CochraneEvidence #Blogshot

🚨ICYMI - Updated Cochrane #SystematicReview: Withdrawal of antihypertensive drugs in older people 💊 doi.org/10.1002/146518… "Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio" #CochraneEvidence #bloodpressure #deprescribing

ICYMI: What happens when invisible/abandoned clinical trials are re-examined? 🔍🤔 Watch Dr. Juan Erviti @DTB_Navarre @RIATinitiative in our TI #BestEvidence webinar: ti.ubc.ca/RIAT #MedEd #medsafety #SegPac #ResearchMethods

Cochrane Library editorial: Achieving sustainable healthcare through deprescribing cochranelibrary.com/cdsr/doi/10.10…

🚨ICYMI - Updated Cochrane #SystematicReview: Withdrawal of antihypertensive drugs in older people 💊 doi.org/10.1002/146518… "Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio" #CochraneEvidence #bloodpressure #deprescribing

🆕Our new Cochrane #SystematicReview protocol: Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists doi.org/10.1002/146518…

ICYMI - Debunking some of the hype in #Hypertension ti.ubc.ca/drugevidence24 Dr. James Wright summarizes latest evidence on #antihypertensives: ⏰ chronotherapy 💊 first line tx 🎯 blood pressure targets ⚠️ tx efficacy + safety #meded #medsafety